Cargando…

Targeted drug combination therapy design based on driver genes

Targeted therapies against cancer types with more than one driver gene hold bright but elusive promise, since approved drugs are not available for all driver mutations and monotherapies often result in resistance. Targeting multiple driver genes in different pathways at the same time may provide an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zsákai, Lilian, Sipos, Anna, Dobos, Judit, Erős, Dániel, Szántai-Kis, Csaba, Bánhegyi, Péter, Pató, János, Őrfi, László, Matula, Zsolt, Mikala, Gábor, Kéri, György, Peták, István, Vályi-Nagy, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731102/
https://www.ncbi.nlm.nih.gov/pubmed/31523388
http://dx.doi.org/10.18632/oncotarget.26985
Descripción
Sumario:Targeted therapies against cancer types with more than one driver gene hold bright but elusive promise, since approved drugs are not available for all driver mutations and monotherapies often result in resistance. Targeting multiple driver genes in different pathways at the same time may provide an impact extensive enough to fight resistance. Our goal was to find synergistic drug combinations based on the availability of targeted drugs and their biological activity profiles and created an associated compound library based on driver gene-related protein targets. In this study, we would like to show that driver gene pattern based customized combination therapies are more effective than monotherapies on six cell lines and patient-derived primary cell cultures. We tested 55–102 drug combinations targeting driver genes and driver pathways for each cell line and found 25–85% of these combinations highly synergistic. Blocking 2–5 cancer pathways using only 2–3 targeted drugs was sufficient to reach high rates of tumor cell eradication at remarkably low concentrations. Our results demonstrate that the efficiency of cancer treatment may be significantly improved by combining drugs against multiple tumor specific drivers.